Skip to main content
. Author manuscript; available in PMC: 2023 Apr 7.
Published in final edited form as: Mol Cancer Ther. 2022 Oct 7;21(10):1573–1582. doi: 10.1158/1535-7163.MCT-22-0192

Figure 4: 1HE co-administration increases the within tumor distribution of trastuzumab-gelonin:

Figure 4:

Shown are representative fluorescence histology images of NCI-N87 xenograft tumor sections that were obtained from mice that were treated with (A) Trastuzumab-gelonin or (B) Trastuzumab-gelonin+1HE. (C) Whole tumor sections were imaged and analyzed to evaluate the percent of the tumor area that stained positive for trastuzumab. Data is presented as the group mean (n=6 Tmab-rGel, 4 Tmab-rGel+1HE) with standard deviation error bars.